Greece's Digital Health Reset: Opportunities Emerge for Local EHR and Interoperability Vendors Amid Lagging IT Infrastructure, Black Book Research
PARIS, FRANCE / ACCESS Newswire / June 8, 2025 / Greece ranks among the lowest-performing nations in Europe across critical digital health benchmarks, according to findings published in the 2025 edition of the Black Book of Global Healthcare Information Technology. The report, based on a Q2 2025 survey of 122 hospital and physician practice administrators in Greece conducted ahead of HIMSS25 Europe, reflects the perspectives of stakeholders on the state of healthcare IT adoption and readiness in the country.
While the findings point to significant challenges in Electronic Health Records (EHR), interoperability, and cybersecurity, they also highlight a unique opportunity for Greek-oriented and regional digital health vendors to accelerate transformation. With dissatisfaction running high among providers and patients, local innovation and targeted vendor partnerships could reshape the national health IT landscape.
EHR Adoption and Vendor Opportunity
Only 14% of Greek providers surveyed reported access to integrated, functional digital health records in routine care. A significant 98% expressed dissatisfaction with current systems, citing fragmented platforms, inefficient workflows, and lack of real-time clinical data access. These gaps open the door for localized EHR vendors to design solutions aligned with national healthcare workflows and policy environments, offering custom platforms that overcome the limitations of foreign, one-size-fits-all technologies.
Interoperability as a Catalyst for Growth
Just 7% of Greek health IT leaders stated their systems are capable of supporting interoperable data exchange across care settings. The lack of HL7 FHIR-standardized integration highlights the pressing need for Greek vendors and regional integration firms to develop scalable, standards-based health data exchange platforms. Opportunities exist for companies positioned to bridge public-private sector silos, modernize legacy systems, and create unified health information networks.
Population Health and Analytics Market Gaps
Only 3% of respondents reported using real-time data analytics or risk stratification tools to support population health initiatives. Vendors focusing on chronic disease management, preventive care, and regional analytics platforms can play a key role in helping Greek healthcare organizations harness data-driven care models that are still in early stages of development.
Cybersecurity Innovation Needs
With 95% of surveyed IT leaders citing significant gaps in cybersecurity, there is growing demand for security-as-a-service, cloud-based protections, and affordable infrastructure assessments tailored to smaller Greek hospitals and clinics. This represents a prime opportunity for cybersecurity firms with healthcare specialization to support compliance, resilience, and trust.
Patient Experience Solutions
In a companion survey, 97% of Greek patients reported never accessing their health records online, and 100% lacked confidence in their provider's digital tools. This signals a strong market opening for vendors offering secure patient portals, mobile health access, and education tools that empower individuals and improve engagement.
Key HIMSS25 Europe Vendors Supporting Greece's Digital Health Needs
Several vendors exhibiting and sponsoring at HIMSS25 Europe in Paris next week stand out as especially well-positioned to support Greece's digital transformation goals. These companies offer technologies directly aligned with the challenges facing Greek healthcare and are prepared to demonstrate scalable solutions that address EHR adoption, interoperability, analytics, and patient engagement.
InterSystems will showcase their advanced data integration and interoperability platforms, which leverage HL7 FHIR to enable seamless data sharing which is an urgent need for fragmented Greek health systems.
Dedalus, a vendor with deep roots in European healthcare, is offering regionally aligned EHR and population health management solutions that address local workflow gaps and regulatory complexities in Greece.
Hyland is exhibiting its Content Innovation Cloud, designed to enhance document-based interoperability, support clinical content access, and reduce administrative burden, an important area for Greek hospitals with legacy infrastructure.
Oracle Health and Epic Systems will also present end-to-end EHR platforms and AI-powered analytics tools that offer Greek providers the opportunity to benchmark against high-functioning, digitally mature health systems, should they be capable of encompassing the needs of the Greek healthcare systems, its providers and patients at a cost the Greek government and providers can afford.
T-Systems, with its cybersecurity and managed IT offerings, will demonstrate solutions ideal for smaller hospitals in Greece needing affordable and scalable security frameworks.
Greek CIOs and provider executives attending HIMSS25 Europe are encouraged to engage with these vendors, explore real-time demos, and evaluate how proven digital technologies can be adapted to Greece's local challenges and accelerate national interoperability progress.
'This report reflects the voices of healthcare professionals and patients in Greece-not an opinion or judgment by our firm,' said Douglas Brown, founder of Black Book Research. 'With the right collaborations, local vendors and regional innovators have a real opportunity to drive digital transformation and close persistent technology gaps.'
'For Greek CIOs and healthcare leaders attending HIMSS25 Europe, this is a pivotal moment to explore firsthand the technologies reshaping connected care across the continent,' Brown added. 'Vendor demonstrations at the exhibition offer strategic insights into scalable interoperability frameworks, AI-driven analytics, secure cloud infrastructures, and patient engagement platforms-all critical components for modernizing Greek healthcare. The opportunity to benchmark with leading systems and meet innovators building regionalized EHR and data exchange solutions should not be missed.'
Furthermore, the 2025 World Index of Healthcare Innovation ranked Greece 26th out of 32 European countries in health digitization, possibly falling to last at 32 in 2026. The report highlighted that Greece is one of the least digitally connected countries in the index, limiting its ability to take full advantage of electronic health records and other digital health technologies.
The 2025 Black Book of Global Healthcare Information Technology provides independent performance evaluations of healthcare IT systems and infrastructure in 44 countries. The Greece-specific findings are intended to guide policymakers, health institutions, and vendors toward high-impact modernization strategies. For more information, visit www.blackbookmarketresearch.com.
About Black Book Research
Black Book Research is a globally recognized, independent market research and public opinion firm specializing in healthcare information technology, services, and consulting. For over a decade, Black Book has surveyed and analyzed the experiences of healthcare executives, clinicians, technology users, and patients across Europe and worldwide. Its annual reports and performance rankings are based on validated client and user feedback from over three million healthcare IT users globally. Black Book maintains a transparent, non-paid methodology, ensuring unbiased evaluations that empower stakeholders to make informed technology decisions and guide digital health transformation strategies. Visit Black Book Research's leadership team at HIMSS 25 Europe in Paris for more information contact them at [email protected]
Contact InformationPress Office 8008637590
SOURCE: Black Book Research
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
1 Stock Down 40% This Year to Buy and Hold
Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio
Fox News
14 hours ago
- Fox News
Francis Ford Coppola's treatment sheds light on heart condition affecting millions
Francis Ford Coppola, director of "The Godfather," was hospitalized in Italy last week for a non-emergency cardiac procedure. The filmmaker, 86, sought to update a "30-year-old AFib procedure," according to a post on his Instagram page. AFib, or atrial fibrillation (AFib), is an "irregular and often rapid heart rhythm" that can raise the risk of blood clots, heart failure, stroke and other heart-related complications, according to the American Heart Association. After Italian media sources reported the director's hospital visit, a representative for Coppola called it a "scheduled update procedure" and said he was "resting nicely." "All is well," according to his representatives. "Da Dada (what my kids call me) is fine," the director said on his social media, speaking for what appears to be the first time about his condition. He continued: "Taking an opportunity while in Rome to do the update of my 30-year-old AFib procedure with its inventor, a great Italian doctor — Dr. Andrea Natale! I am well!" Dr. Bradley Serwer, an interventional cardiologist and chief medical officer at VitalSolution, an Ingenovis Health company, spoke with Fox News Digital about the condition. "AFib is typically not immediately life-threatening, but it can lead to complications or issues in the future," said the cardiologist, who has not treated Coppola. With AFib, the normal electrical activity in the heart changes to chaotic electrical signals, according to the Maryland-based cardiologist. This causes the heart to beat quickly and get out of rhythm. Instead of contracting normally, the upper chambers of the heart — called atria — start to quiver, causing blood clots to form. "When these clots break free, they can travel to the brain, causing a stroke," Serwer cautioned. For many people, AFib may have no symptoms, but for some, it can cause a fast or pounding heartbeat, shortness of breath or lightheadedness. "AFib can be challenging due to its diverse manifestations," Serwer noted. There are several procedural approaches to treat atrial fibrillation, according to the cardiologist. The most common procedure is called an ablation, which is when a specialized cardiologist uses catheters to follow the heart's electrical activity. The doctor then burns the sites where the AFib begins. "This procedure has a high rate of success and complications are low, making it a highly valued option," Serwer noted. If a patient is undergoing open-heart surgery for coronary artery disease or valvular heart disease, a surgeon can perform a "maze procedure," which creates a "maze-like pattern of scar tissue" in the upper chambers of the heart to block irregular electrical signals, according to Mayo Clinic. There are also procedures to reduce the risk of stroke in patients who have AFib, but who may not be able to take blood thinners. By placing a small device where blood clots form, the rate of stroke drops significantly, Serwer said. In some cases of atrial fibrillation, the condition can come and go, but other patients may experience persistent AFib, the cardiologist said. For more Health articles, visit While it's not usually life-threatening, AFib is still considered a serious medical condition that requires proper treatment. Serwer advised, "If you experience sudden-onset dizziness or palpitations that persist, it is imperative to seek immediate evaluation from a medical professional."
Yahoo
16 hours ago
- Yahoo
New Dad, 29, Was Told He Had Tonsillitis. He Died the Next Day
"Watching Jacob grow up without his daddy by his side is devastating and we miss Michael every single day," Charlotte Reynolds said NEED TO KNOW A new father died a day after he was allegedly misdiagnosed with tonsillitis Michael Reynolds, 29, actually had the potentially fatal condition epiglottitis, which causes a swelling of the flap at the top of the windpipe He had a seizure at home and later died of cardiac arrest, caused by a lack of oxygen, per his family's law firm, Irwin Mitchell A new father died a day after doctors allegedly misdiagnosed him with tonsillitis. Michael Reynolds, a 29-year-old truck driver, first sought medical care on November 29, 2023, when he complained of a lingering cough and sore throat. He was prescribed a steroid nasal spray and referred for a chest X-ray, according to a statement from the family's law firm, Irwin Mitchell. Michael's condition deteriorated the following day, and he returned to his doctor's office, where he saw a different physician. At the time, Michael said he felt like his throat was closing up, and he was spitting saliva into a bowl because he couldn't swallow. He was allegedly diagnosed with tonsillitis — inflammation of the tonsils — and prescribed oral antibiotics. The family's law firm alleges it was 'not made clear' to Michael that he should go to the emergency room. After leaving the doctor's office, Michael and his wife, Charlotte, picked up his antibiotics from the pharmacy and returned to their home in Boston, Lincolnshire, in the U.K. The next morning, Michael had a seizure; Charlotte called an ambulance which took him to the hospital, where he died on Dec. 1, 2023. According to Irwin Mitchell, the coroner found that Michael had epiglottitis, which is a swelling of the flap that covers the windpipe. As the Cleveland Clinic explains, it's an uncommon condition, most likely caused by a bacterial infection, and shouldn't be treated at home. According to the Clinic, "It's essential to get to the emergency room (ER) immediately if you or a loved one is experiencing symptoms of epiglottitis. Epiglottitis is a medical emergency." The epiglottitis and upper airway obstruction led to Michael's hypoxic cardiac arrest — aka, cardiac arrest caused by a lack of oxygen. Per Irwin Mitchell, an inquest into his death found there was a 'missed opportunity' to give Michael 'robust advice' to go to the emergency room, per the coroner, who explained that staff there would likely have been more familiar with the condition. 'This is a truly tragic case where a young dad has lost his life. Charlotte and the rest of Michael's family are understandably struggling to come to terms with losing him so suddenly and unexpectedly, and under such circumstances,' Rosie Charlton, the family's attorney, said. 'They've also had a number of concerns about the events that unfolded in the lead up to Michael's death. Worryingly, the inquest has validated those concerns.' 'Watching Jacob grow up without his daddy by his side is devastating and we miss Michael every single day,' Charlotte, whose son is now 3, said in the Irwin Mitchell statement. "Michael meant everything to us and losing him has left a huge hole in our lives that will never go away. We'd do anything to bring him back.' PEOPLE has reached out to Charlotte Reynolds for further comment. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Her statement to Irwin Mitchell continued: 'All I can hope for now is that by sharing our story, it can lead to improvements in care for others and more awareness around the signs of epiglottitis and the need for emergency treatment, as it's something I'd never even heard of before.' 'I wouldn't want anyone going through what we have.' Read the original article on People Solve the daily Crossword
